Kanika Monga, MD, of the American College of Rheumatology’s (ACR) Communication and Marketing Committee, and Angus Worthing, MD, an ACR director, discuss the ACR's recent survey on rheumatology.
A recent survey conducted by the American College of Rheumatology (ACR) indicated that a large portion of patients with rheumatic diseases were unsure if they had been prescribed a biosimilar before, suggesting a major knowledge gap among patients on how biosimilars differ from reference biologics.
Additionally, the survey showed a 52% decline in the percentage of respondents who said they were currently being treated by a rheumatologist, vs the number under treatment a year earlier. Patients also reported that wait times to be seen by a rheumatologist increased between 2019 and 2020. Both of these findings were likely partly due to the coronavirus disease 2019 (COVID-19) pandemic that has changed how practices conduct business and deprived some patients of the economic means and health insurance to continue seeing their provider.
We sat down with Kanika Monga, MD, a rheumatologist at Houston Methodist Hospital in Texas and a member of the ACR’s Communication and Marketing Committee, and Angus Worthing, MD, a rheumatologist at Arthritis and Rheumatism Associates, PC, in Chevy Chase, Maryland, a member of the board of directors of the ACR, to discuss the results of this survey and what the rheumatology field is expected to look like post-COVID-19.
To learn more about the ACR’s survey, click here.
To learn more about COVID-19’s impact on biosimilars, check out our ebook here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
October 18th 2020We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.